Technical Analysis for CLRB - Cellectar Biosciences, Inc.

Grade Last Price % Change Price Change
grade B 2.36 3.06% 0.07
CLRB closed up 3.06 percent on Friday, September 13, 2019, on 11.31 times normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical CLRB trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Upper Bollinger Band Walk Strength 3.06%
Overbought Stochastic Strength 3.06%
Upper Bollinger Band Touch Strength 3.06%
Pocket Pivot Bullish Swing Setup 0.00%

Older signals for CLRB ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Cellectar Biosciences, Inc., a development stage biopharmaceutical company, develops compounds for the treatment and imaging of cancer. Its proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. The company also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as is in Phase Ib dose-escalation trial for patients with advanced solid tumors; and CLR1404, a cancer-targeted chemotherapy. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.
Medicine Cancer Clinical Medicine Imaging Oncology Chemotherapy Stem Cells Radiation Antineoplastic Drugs Occupational Safety And Health Radiation Therapy Glioblastoma Targeted Therapy Tomography Solid Tumor Advanced Solid Tumors Ros1
Is CLRB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.28
52 Week Low 1.22
Average Volume 113,635
200-Day Moving Average 2.1339
50-Day Moving Average 2.1572
20-Day Moving Average 2.1825
10-Day Moving Average 2.229
Average True Range 0.1212
ADX 21.13
+DI 25.8742
-DI 6.8409
Chandelier Exit (Long, 3 ATRs ) 2.2364
Chandelier Exit (Short, 3 ATRs ) 2.4036
Upper Bollinger Band 2.3563
Lower Bollinger Band 2.0087
Percent B (%b) 1.01
BandWidth 15.92669
MACD Line 0.045
MACD Signal Line 0.0193
MACD Histogram 0.0257
Fundamentals Value
Market Cap 32.85 Million
Num Shares 13.9 Million
EPS -1.13
Price-to-Earnings (P/E) Ratio -2.09
Price-to-Sales 0.00
Price-to-Book 1.98
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.80
Resistance 3 (R3) 2.83 2.71 2.72
Resistance 2 (R2) 2.71 2.60 2.70 2.70
Resistance 1 (R1) 2.54 2.53 2.48 2.51 2.67
Pivot Point 2.42 2.42 2.40 2.41 2.42
Support 1 (S1) 2.25 2.31 2.19 2.22 2.05
Support 2 (S2) 2.13 2.24 2.12 2.02
Support 3 (S3) 1.96 2.13 2.00
Support 4 (S4) 1.93